Novartis | NOVN - Assets

Stock Price
114.72
Daily Change
0.64 0.56%
Monthly
-4.26%
Yearly
21.77%
Q2 Forecast
111.47

Novartis reported $110.95B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Alcon AG USD 31.56B 31M Dec/2025
Almirall EUR 2.34B 29.21M Dec/2025
Amgen USD 90.59B 445M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Autolus Therapeutics Ltd USD 589.07M 72.88M Dec/2025
Bayer EUR 104.54B 331M Dec/2025
Biogen USD 29.44B 232M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Fresenius EUR 42.46B 1.14B Sep/2025
Fresenius Medical Care EUR 31B 115.33M Dec/2025
Galapagos EUR 3.41B 105.39M Dec/2025
Genmab DKK 12.87B 5.85B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
GRIFOLS EUR 19.71B 141.77M Dec/2025
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
J&J USD 200.89B 1.68B Mar/2026
Lonza CHF 18.97B 164M Dec/2025
Merck EUR 51.53B 600M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Novartis USD 110.95B 3.66B Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Novo Nordisk DKK 542.9B 30.61B Dec/2025
Orion EUR 2.08B 69.2M Mar/2026
Pfizer USD 208.73B 2.64B Sep/2025
Philips EUR 26.94B 605M Dec/2025
Recordati EUR 5.3B 122.58M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 128.02B 1.22B Mar/2026
UCB EUR 18.16B 971M Dec/2025